Skip to main content

Table 1 Ongoing clinical trials of new drugs against retinal and choroidal angiogenesis

From: Retinal and choroidal angiogenesis: a review of new targets

NCT number

Drug

Target/mechanism

Phase

Conditions

NCT02543229

OPT-302

VEGF-C VEGF-D

1

Eye diseases, macular degeneration, retinal diseases, retinal degeneration, pathologic neovascularization

NCT02591914

E10030 (Fovista)

PDGF

1

Neovascular age-related macular degeneration

NCT01940887

3

NCT02348359

X-82

VEGF

2

Age-related macular degeneration, macular degeneration, exudative age-related macular degeneration, age-related macular degeneration, eye diseases, retinal degeneration, retinal diseases

PDGF

NCT02699450

RO6867461

VEGF

2

Diabetic macular edema

ANG-2

NCT02530918

DS-7080ª

Robo-4

1

Neovascular age-related macular degeneration

NCT02727881

OHR-102 (Squalamine lactate)

VEGF

3

Age-related macular degeneration

PDGF

bFGF

NCT02857517

Conbercept

VEGF-A

2

Proliferative diabetic retinopathy, idiopathic choroidal neovascularization, retinal vein occlusion, polypoidal choroidal vasculopathy, branch retinal vein occlusion, macular edema, neovascular glaucoma, age-related macular degeneration, pathological myopia, diabetic macular edema, wet age-related macular degeneration

NCT02911311

 

VEGF-B

NP

 

NCT03108352

 

VEGF-C

3

 

NCT03159884

 

PlGF

4

 

NCT03154892

  

NP

 

NCT03128463

  

NP

 

NCT02194634

  

3

 

NCT03054818

  

NP

 

NCT01024998

AAV2-sFLT01

Vector to neutralizes VEGF

1

Macular degeneration, age-related maculopathies, age-related maculopathy, retinal degeneration, retinal neovascularization, gene therapy, eye diseases

NCT02307682

RTH258 (Brolucizumab)

VEGF-A

3

Neovascular age-related macular degeneration

NCT02434328

    

NCT02713204

REGN910 (Nesvacumab)

Inactivates the Tie2 receptor ligand ANG-2

2

Neovascular age-related macular degeneration

NCT02555306

DE-122

Endoglin

2

Age-related macular degeneration

NCT02914639

SF0166 Topical Ophthalmic Solution

Integrin αvβ3

2

Age-related macular degeneration

NCT02462928

Abicipar pegol

VEGF

3

Macular degeneration

PDGF

NCT02867735

LKA651

Erythropoietin

1

Macular edema, diabetic macular edema, neovascular age-related macular degeneration, retinal vein occlusions

NCT02613559

TK001 (Sevacizumab)

VEGF

1

Neovascular age-related macular degeneration

NCT02484690

RG7716

VEGF

2

Macular degeneration, choroidal neovascularization

ANG-2

NCT03066258

RGX-314 gene therapy

VEGF

1

Neovascular age-related macular degeneration, wet age-related macular degeneration

  1. From http://www.clinicaltrials.gov. Accessed June 11, 2017. Searched terms: ocular angiogenesis, age-related macular degeneration, retinal neovascularization, choroidal neovascularization; Recruitment: “closed studies/active, not recruiting” AND “open studies/recruiting”. Abbreviations: ANG-2, angiopoietin-2; bFGF, Basic fibroblast growth factor; NCT, National Clinical Trial; PlGF, Placental growth factor; Robo-4, Roundabout Guidance Receptor-4; NP, not provided; VEGF, vascular endothelial growth factor